Navigation Links
China's Type 2 Diabetes Market Will Grow To $3.5 Billion In 2017
Date:8/8/2013

BURLINGTON, Mass., Aug. 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the type 2 diabetes therapeutic market in China, the third largest after the United States and Japan, will grow 10 percent annually, reaching $3.5 billion in 2017.  Fueling this expansion are the growing number of drug-treated patients and the increasing use of dipeptidyl peptidase-4 (DPP-IV) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and insulin analogues.

The Emerging Markets report entitled Type 2 Diabetes in China finds that, although further generic erosion of older oral antidiabetics is expected, recently launched DPP-IV inhibitors (Merck's Januvia/Janumet, Bristol-Myers Squibb/AstraZeneca's Onglyza, Novartis's Galvus) and GLP-1 receptor agonists (Bristol-Myers Squibb/AstraZeneca's Byetta, Novo Nordisk's Victoza) will continue to enjoy market exclusivity and garner higher patient share in China during the 2012-2017 period. Biosimilar versions of insulin analogues, both long- and short-acting, will have only a modest impact on China's type 2 diabetes market during the forecast period. Most biosimilar insulins are only fractionally less expensive than the originators, which encourages physicians and patients to stay with branded insulins. Together with the launches of additional novel agents, Western-branded therapies will consistently capture more than 70 percent of sales in China's type 2 diabetes therapeutic market by 2017.

The findings also reveal that Chinese physicians show strong interest in DPP-IV inhibitors and GLP-1 receptor agonists. DPP-IV inhibitors are favored because of their improvement in glycemic control without the risk of hypoglycemia. GLP-1 receptor agonists are effective in lowering HbA1c and body weight and therefore are ideal for obese type 2 diabetes patients. However, due to their high prices and lack of reimbursement, physicians who currently prescribe them do so mostly in the second- or third-line setting, after their patients fail to maintain glycemic control with less expensive options. Meanwhile, patients need to be in good financial standing to afford the high out-of-pocket payment.

"More than 95 percent of Chinese residents have access to some form of government-sponsored medical insurance, but broad access does not translate into affordable healthcare," said Decision Resources Analyst Jing Wu, M.S., M.B.A. "Select DPP-IV inhibitors and GLP-1 receptor agonists have a reasonable chance of being included on the next version of the National Reimbursement Drug List (NRDL), likely to be released in 2014. However, in order to control treatment costs, the reimbursement of these agents will be restricted to specific type 2 diabetes patient groups."

The new report features extensive primary research with Chinese physicians as well as a market outlook through 2017.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
2. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
3. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
4. CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
7. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
9. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
10. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
11. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading ... 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... in the life sciences, offering exclusive access to key decision makers who influence ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician ... spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as ... the first in Arkansas to introduce the most powerful SCS system and the only ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
(Date:5/26/2017)... ... 26, 2017 , ... via seating is proud to partner ... chair specifically designed for clinical areas. Genie Copper Mesh is a crossover chair ... to provide customers with a game changing chair that is affordably priced,” Chas ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on Kickstarter ... to be available at a discounted crowdfunding price on Indiegogo . , “Along ... I also wanted to bring a fidget toy to the market that was made ...
Breaking Medicine News(10 mins):